Replies to post #291884 on Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

2-3 Approvals Imminent.

ELTP

[conix]

The rush is on by buyers getting into ELTP after that awesome Conference Call.

Still waiting for undeniably positive news before going in for another trade.

GLTA

[NASDAQ2020]

The SunGen ANDA #2 is 10-12 months from Approval

This one is Bigger than SequestOx

SunGen ANDA #2 (The Avatar) undisclosed CNS stimulant $1.6 Billion market with ONLY 3 competitors to the name brand.
Elite will split the Generic money with 3 competitors.

FDA busy reviewing submission currently.
We have 10-12 months to take advantage before Approval.

This helpful info contributed to the board by N2K shows an average amount we might receive. It could be MUCH more due to so few competitors.

Quote:



For a product entering a growth market with existing product market leaders having more than a three year lead time, there has been a first year average market capture of 8.7%. If we extrapolate that to Elite and the CNS ER product for the $1.6 B market it is (that's right) $139.2 Million in the first year. And, with the Glenmark partnership as the commercialization engine, it could be better that the other two I found in my research, because Glenmark is more capable than the other two had as commercial partners.
Quote:


SunGen ANDA #3 even BIGGER than the above. approval 2019 for this one